# Dana V. Rizk

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dana-v-rizk/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,894 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 34 |
| i10-index | 57 |
| Last Known Institution | University of Alabama at Birmingham |
| OpenAlex ID | https://openalex.org/A5000517864 |
| ORCID iD | 0000-0002-6877-2811 |
| Works | 178 |

## Researcher papers

Showing 12 of 15.

- [Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy](https://scholariq.org/papers/rituximab-or-cyclosporine-in-the-treatment-of-membranous-nephropathy/)
- [Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-sparsentan-versus-irbesartan-in-patients-with-iga/)
- [IgA Nephropathy: An Interesting Autoimmune Kidney Disease](https://scholariq.org/papers/iga-nephropathy-an-interesting-autoimmune-kidney-disease/)
- [Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial](https://scholariq.org/papers/sparsentan-in-patients-with-iga-nephropathy-a-prespecified-interim-analysis-from/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy](https://scholariq.org/papers/the-origin-and-activities-of-iga1-containing-immune-complexes-in-iga-nephropathy/)
- [Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy](https://scholariq.org/papers/alternative-complement-pathway-inhibition-with-iptacopan-in-iga-nephropathy/)
- [The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy](https://scholariq.org/papers/the-emerging-role-of-complement-proteins-as-a-target-for-therapy-of-iga/)
- [Dietary Patterns and Risk of Death and Progression to ESRD in Individuals With CKD: A Cohort Study](https://scholariq.org/papers/dietary-patterns-and-risk-of-death-and-progression-to-esrd-in-individuals-with/)
- [CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease](https://scholariq.org/papers/curegn-study-rationale-design-and-methods-establishing-a-large-prospective/)
- [An Update on Current Therapeutic Options in IgA Nephropathy](https://scholariq.org/papers/an-update-on-current-therapeutic-options-in-iga-nephropathy/)
- [New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies](https://scholariq.org/papers/new-treatment-strategies-for-iga-nephropathy-targeting-plasma-cells-as-the-main/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Complement system in diseases](https://scholariq.org/topics/complement-system-in-diseases/)
- [Platelet Disorders and Treatments](https://scholariq.org/topics/platelet-disorders-and-treatments/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)

## Researcher university

- [University of Alabama at Birmingham](https://scholariq.org/institutions/university-of-alabama-at-birmingham/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.